Formulation of long-acting levonorgestrel butanoate injectable depot suspension
US12290523B2 · kind B2 · utility
0Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 23, 2017 |
| Grant date | May 6, 2025 |
| Priority date | — |
| Expiry date | Feb 23, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin/progesterone-sensitive reproductive tract dysfunctions and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.